LIN BIOSCIENCE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.7 TWD | -7.46% |
|
-16.33% | -37.98% |
| 2023 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
ETFs positioned on Lin BioScience, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | -1.38% | - |
LIN BIOSCIENCE, INC. is a Taiwan-based company mainly engaged in the development of new pharmaceutical drugs. The Company is in the research and development and clinical trials stage. It has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -37.98% | 185M | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 6696 Stock
- Funds and ETFs Lin BioScience, Inc.
